e remaining one million common shares through the facilities of the TSX under this normal course issuer bid. The Securities Repurchase Program will terminate on November 7, 2011 or at such time as Valeant completes its purchases. The normal course issuer bid will remain in effect until the earliest of November 7, 2011, the termination of the bid by the Company,
or until the Company has purchased the maximum number of shares permitted under the bid. To date, the Company has purchased 14,969,599 Common Shares
through the facilities of the New York Stock Exchange at a volume weighted average purchase price of U.S.$39.46 per share.
Valuation analyses of the Company were prepared by the Company's financial advisors in connection with the preparation of such advisor's fairness opinions provided in connection with the merger between Biovail Corporation (now Valeant) and Valeant Pharmaceuticals International (now a wholly-owned subsidiary of Valeant) in September 2010. Descriptions and summaries of such valuation analyses, and the corresponding fairness opinions, are contained in the Company's Amendment No. 1 to the Registration Statement on Form S-4 filed on August 18, 2010, copies of which are available on SEDAR at www.sedar.com and on the U.S. Securities and Exchange Commission (the "SEC") website at www.sec.gov.
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.
Caution Regarding Forward-Looking Information
To the extent any statements made in this
Page: 1 2 3 Related medicine technology :1
|SOURCE Valeant Pharmaceuticals International, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Valeant Pharmaceuticals Completes Acquisition of Sanitas Group2
. Valeant Pharmaceuticals Announces Resignation of Michael Van Every From Valeants Board of Directors3
. Valeant Pharmaceuticals Reports 2011 Second Quarter Financial Results4
. Valeant Pharmaceuticals Announces Approval of Sublinox® in Canada5
. Valeant Pharmaceuticals Announces Distribution Agreement for Zuacta™ in Canada6
. Valeant Pharmaceuticals Agrees to Acquire Ortho Dermatologics7
. Sanofi Divests Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc.8
. Valeant Pharmaceuticals Agrees to Acquire Dermik9
. Valeant Pharmaceuticals Announces License Agreement With Meda for North American Rights for Elidel® and Xerese™10
. Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results11
. Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction